CoChat
Sign Up
Cited by 306Cannabis and Cannabinoid ResearchMedicinal Plant Extracts EffectsPsychedelics and Drug Studies

The DOI matches its Crossref record; 211 of the 213 references it cites were found in a registry or an index.

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Open access
García-Gutiérrez, María S., Navarrete, Francisco, Gasparyan, Ani, Austrich-Olivares, Amaya, Sala, Francisco, Manzanares, Jorge·2020·Biomolecules
DOI 10.3390/biom10111575PMC PMC7699613
Open this paper in CoChat — free accountOpen PDF

Abstract

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB1r and CB2r), 5-HT1A receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom10111575

Cites

211 of 211 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of the main hypothesized mechanisms described for the anxiolytic, antidepressant and antipsychotic actions of CBD. AEA: anandamide; 5-HT1A: serotonin receptor 1A; BDNF: brain delivered neurotrophic factor; CB1r: cannabinoid CB1 receptor; CB2r: cannabinoid CB2 receptor; ChAT: choline acetyltransferase; D2: dopamine receptor D2; DNA methyl: DNA methylation; ECS: endocannabinoid system; FAAH: fatty acid amide hydrolase; HPA axis: hypothalamus pituitary-axis; M1/M4r: muscarinic receptor 1 and 4; PPARγ: peroxisome proliferator activated receptor gamma; TRKb/mTOR: tropomyosin-receptor-kinase B/mammalian target of rapamycin; TRPV1: transient receptor potential cation channel subfamily V member 1.
Figure 1 Schematic representation of the main hypothesized mechanisms described for the anxiolytic, antidepressant and antipsychotic actions of CBD. AEA: anandamide; 5-HT1A: serotonin receptor 1A; BDNF: brain delivered neurotrophic factor; CB1r: cannabinoid CB1 receptor; CB2r: cannabinoid CB2 receptor; ChAT: choline acetyltransferase; D2: dopamine receptor D2; DNA methyl: DNA methylation; ECS: endocannabinoid system; FAAH: fatty acid amide hydrolase; HPA axis: hypothalamus pituitary-axis; M1/M4r: muscarinic receptor 1 and 4; PPARγ: peroxisome proliferator activated receptor gamma; TRKb/mTOR: tropomyosin-receptor-kinase B/mammalian target of rapamycin; TRPV1: transient receptor potential cation channel subfamily V member 1.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 213 references

Research works printed but not linked: 5

  1. Patel, V., Laxminarayan, R., Medina-Mora, M.L., Dua, T., and Chisholm, D. (2016). Chapter 2 Global burden of mental, neurological and substance use disorder: An analysis from the global burden of disease study 2010. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, The International Bank for Reconstruction and Development. [3rd ed.].
  2. Hawksworth, G.M.K. (2004). Metabolism and Pharmacokinetics of Cannabinoids, Pharmaceutical Press.
  3. Sylantyev, S.J.T., Ross, R.A., and Rusakov, D.A. (2011, January 12–16). The enigmatic receptor GPR55 potentiates neurotransmitter release at central synapses. Proceedings of the Neuroscience Meeting Planner Washington, DC: Society for Neuroscience Online: Program, Washington, DC, USA. Program 653.01, Poster B28.
  4. Heather, A., Church, A.C., and Lucey, J.V. (2012). Core Psychiatry, Elsevier. [3rd ed.].
  5. Aragones, 2009, Comorbidity of major depression with other common mental disorders in primary care patients, Aten Primaria, 41, 545

Cited by

Sorted by citations

Items 201–300 of 306

Related

See all

Metadata

Authors
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J.
Affiliations
  • Neurosciences Institute, University Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
  • Consejo Superior de Investigaciones Científicas (ES)
Corresponding author
Manzanares, Jorge
ORCID
Venue
Biomolecules
Publisher
MDPI AG
Published
2020-11-19
Volume
10
Issue
11
Pages
1575
ISSN
2218-273X (ISSN-L)
DOI
10.3390/biom10111575
PMC
PMC7699613
OpenAlex
W3101299715
Cited by
306
References
213
Citations by year
2026: 24 · 2025: 79 · 2024: 62 · 2023: 66 · 2022: 46 · 2021: 29
FWCI
4.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
cannabidiol, anxiety, depression, psychosis, anxiolytic effects, antidepressant effects, antipsychotic effects, tetrahydrocannabinol, phytocannabinoids, cannabinoid receptors, CB1 receptor, CB2 receptor, 5-HT1A receptor, neurogenesis, dose-dependent effects, route of administration, clinical trials, risk-benefit profile
MeSH terms
Animals, Anxiety, Cannabidiol, Depression, Dose-Response Relationship, Drug, Drug Administration Routes, Humans, Psychotic Disorders, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review